Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective-Reference-Cited by-同舟云学术

Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective

Published:2007-09-10 Issue:11 Volume:61 Page:1805-1811
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:

Author:

Roze S.,Ferrières J.,Bruckert E.,Van Ganse E.,Chapman M. J.,Liens D.,Renaudin C.

Publisher

Hindawi Limited

Subject

General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2007.01546..x/fullpdf

Reference31 articles.

1. Economic burden of cardiovascular diseases in the enlarged European Union;Leal;Eur Heart J,2006

2. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III);JAMA,2001

3. International Atherosclerosis Society Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease 2003 http://www.athero.org

4. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice;De Backer;Eur Heart J,2003

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus;Current Problems in Cardiology;2022-04

2. Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe;PHARMACOECONOMICS;2018

3. Niacin for primary and secondary prevention of cardiovascular events;Cochrane Database of Systematic Reviews;2017-06-14

4. Niacin for primary and secondary prevention of cardiovascular events;Cochrane Database of Systematic Reviews;2012-03-14

5. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis;Endocrine Practice;2012-03